Clinical trials: Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid Arthritis
Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France
An observational study to describe the effectiveness, safety, and patient-reported outcomes (PROs) in participants with moderate to severe active rheumatoid arthritis (RA) in France receiving filgotinib in real-world setting.
- Trial name
- PARROTFISH (NCT05323591)
- Testing
- Filgotinib
- Where
- 17 sites in France
- Volunteers
- 155 people
- Sponsor
- Alfasigma S.p.A.
RA
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
Primary Objective: To collect real-use data of the sarilumab auto-injector device (AID) used by rheumatoid arthritis (RA) participants.
- Trial name
- SARIL-RA-EASY (NCT02057250)
- Testing
- Sarilumab, Auto-Injector Device (AID), Pre-filled Syringe (PFS)
- Where
- 53 sites in United States, Chile and 4 more
- Volunteers
- 217 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
The primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) in subjects with moderately…
- Trial name
- CREDO 4 (NCT03120949)
- Testing
- Olokizumab 64 mg SC q4w, Olokizumab 64 mg SC q2w, Concomitant treatment
- Where
- 239 sites in United States, Argentina and 16 more
- Volunteers
- 2,106 people
- Sponsor
- R-Pharm International, LLC
Rheumatoid Arthritis
CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis
CMAB008 is an infliximab biosimilar candidate. The host cell of Remicade is mouse myeloma SP2/0 cell, however, the host cell of CMAB008 is CHO (Chinese hamster ovary cell).
- Trial name
- NCT03478111
- Testing
- CMAB008, MTX, Remicade
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Shanghai Biomabs Pharmaceutical Co., Ltd.
Rheumatoid Arthritis
Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to further investigate rituximab in the treatment of rheumatoid arthritis and to evaluate magnetic resonance imaging of the joints as a possible method to improve the evaluation of treatments.
- Trial name
- NCT00425932
- Testing
- Rituximab
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Gaylis, Norman B., M.D.
Rheumatoid Arthritis
Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD
This is a multicenter, randomized, double-blind, parallel, placebo- and active comparator- controlled clinical study conducted in patients with moderately to severely active RA and an inadequate response to at least one DMARD…
- Trial name
- NCT07423533
- Testing
- GenSci120 150 mg, GenSci120 600 mg, GenSci120 1000 mg
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)
This 3 arm study will compare the safety and efficacy, with respect to a reduction in signs and symptoms and prevention of joint damage, of tocilizumab versus placebo, both in combination with methotrexate (MTX) in patients with…
- Trial name
- NCT00106535
- Testing
- tocilizumab [RoActemra/Actemra], Methotrexate
- Where
- 152 sites in United States, Australia and 14 more
- Volunteers
- 1,196 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs
The study objective of Period 1 (Day 1 to Week 24) is to compare the safety and efficacy of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of participants with moderately to…
- Trial name
- SELECT-BEYOND (NCT02706847)
- Testing
- Upadacitinib
- Where
- 188 sites in United States, Australia and 25 more
- Volunteers
- 499 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT05460832
- Testing
- MBS2320 5 mg, MBS2320 20 mg, MBS2320 40 mg
- Where
- 46 sites in Bosnia and Herzegovina, Bulgaria and 6 more
- Volunteers
- 248 people
- Sponsor
- Modern Biosciences Ltd
Rheumatoid Arthritis
Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis
This is a multicenter, randomized, double-blind, placebo and tocilizumab controlled phase II trial in RA patients to evaluate the initial efficacy, safety, pharmacokinetic, pharmacodynamic characteristics, and immunogenicity of…
- Trial name
- NCT05957107
- Testing
- Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
- Where
- 15 sites in China
- Volunteers
- 181 people
- Sponsor
- Beijing VDJBio Co., LTD.
Sjogren's Syndrome (SS)
An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)
Sjogren's syndrome (SS) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement.
- Trial name
- NCT05217472
- Testing
- Ravaglimab, Ravagalimab
- Where
- Netherlands
- Sponsor
- AbbVie
Rheumatoid Arthritis
Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients With Rheumatoid Arthritis
The goal of this clinical trial is to evaluate the efficacy of FBL-MTX administered by subcutaneous route in Rheumatoid Arthritis patients.
- Trial name
- NCT06565273
- Testing
- FBL-MTX
- Where
- 8 sites in Portugal
- Volunteers
- 40 people
- Sponsor
- SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd